Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer
The addition of bevacizumab to paclitaxel plus carboplatin in the 1st line treatment of
patients with advanced or metastatic non small cell lung cancer (NSCLC) provided a survival
benefit. There are patients with NSCLC who have not received bevacizumab and have relapsed
after 1st and/or 2nd line therapy. The evaluation of bevacizumab plus chemotherapy in such
patients is justified. The combination of paclitaxel and carboplatin, administered every two
weeks, has a favorable toxicity profile. This study will evaluate the addition of
bevacizumab to a biweekly regimen of paclitaxel and carboplatin as 2nd or 3rd line therapy
for NSCLC
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate
Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)
No
Sofia Agelaki, MD
Principal Investigator
University Hospital of Crete
Greece: National Organization of Medicines
CT/08.17
NCT00753909
November 2008
March 2013
Name | Location |
---|